Pemazyre Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England
NICE Said No To Bavencio For Urothelial Cancer
Executive Summary
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.